An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Quince Therapeutics, Inc. (Nasdaq: QNCX) announced that their CEO and CMO will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will be accessible via a live webcast on the company's Investor Relations website.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, a virtual event, on Wednesday, February 14, 2024 beginning at 10:40 a.m. Eastern Time.
A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.
About Quince Therapeutics
Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the potential of a patient’s own biology to deliver innovative and life-changing therapeutics to those living with rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, and Twitter/X.
Media & Investor Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com
Source: Quince Therapeutics, Inc.
FAQ
When will Dirk Thye, M.D. present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference?
Dirk Thye, M.D. will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 10:40 a.m. Eastern Time.
Where can I access the live webcast of the presentation?
The live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com.
Will there be an archive of the webcast available?
Yes, an archive of the webcast will be available shortly following the end of the live event.
cortexyme is developing therapeutics based on data supporting a new theory of the cause of alzheimer's and other degenerative disorders. cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration and beta amyloid production. the target has been validated in a number of animal models and cortexyme is currently moving a proprietary small molecule towards human clinical testing.
